To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
HTG Presents Testing Platform for all Sample Types
HTG, Inc. has announced the availability of the qSeries™ ArrayPlate, a variety of mRNA array products ranging from preconfigured to customized arrays.
The qSeries features the qFix™ ArrayPlates, a choice of standard arrays for ready-to-run assays; the qFLEX™ ArrayPlates, semi-customized assays developed from a catalog list of genes (GeneSet™ reagents); and the qCustom™ ArrayPlates, fully customized assays built to order.
The qSeries is built on HTG’s qNPA™ (quantitative Nuclease Protection Assay) technology that enable simultaneous, multiplexed measurement of RNA levels, DNA expression and protein function.
The qSeries offers highly accurate, sensitive and reproducible test results without the need for extraction, amplification or labeling requirements. The same simple, lysis-only protocol is used for all sample types including cultured cells, fresh, frozen or FFPE tissue sections, and whole organisms are used.
• qFix ArrayPlates enable researchers to select from 12 preconfigured arrays that provide analysis for the most common research areas including toxicology, cardiology, oncology, inflammation and apoptosis without developing customized plates. The qFix ArrayPlates provide an economic option for researchers that require high-quality analysis but have had difficulty accessing this technology due to budget constraints.
• qFlex ArrayPlates offers clients a specialized array without the expense and complexity of developing a fully customized array. Clients can choose from a variety of GeneSet reagents to create an array with the content fitting their needs.
• qCustom ArrayPlates provides customers with the option of building fully customized arrays. The arrays are developed in accordance with customers’ specifications and needs allowing for complete control over the research design and use of genes that are not in HTG’s catalog.
“HTG developed the qSeries to meet the diverse needs of its client portfolio. By offering a variety of assays ranging from preconfigured to fully customized, we are able to satisfy the needs of academic researchers, as well as researcher’s at large pharmaceutical companies,” said E. William Radany, Ph.D., Chief Executive Officer, HTG.